ADVM Adverum Biotechnologies: Earnings growth forecast for next year

Corporate emblem and logo of Adverum Biotechnologies (ADVM)

The projected growth in earnings per share for the next fiscal year demonstrates the potential of Adverum Biotechnologies (ADVM), where the 32.40 metric serves as the target level. Adverum Biotechnologies is implementing revolutionary gene therapy that replaces regular injections for vision loss, promising high margins. The proprietary Ixo-vec vector transforms eye tissues into a drug source. Experienced management is successfully preparing the infrastructure for the final stages of trials.

ADVM: Adverum Biotechnologies Projected earnings per share growth rate for next year 07/04/2022 - 12/20/2025

Metric breakdowns and analytics for Adverum (ADVM)

Fundamental company valuation:adverum.com
Finished products of Adverum Biotechnologies Inc.

For Adverum Biotechnologies (ADVM), the change in the consensus earnings per share forecast reflects aggregated market expectations regarding the business's future profitability. This indicator measures the percentage deviation of next year's expected earnings from current values, signaling a revision of the company's financial stability. For ocular gene therapy, this metric is critically sensitive to clinical trial results and insurance reimbursement risks for treatment costs.

Main competitors

ALC (Alcon Corp) - Earnings growth forecast for next year|Bausch + Lomb Corporation (BLCO) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year GKOS|Earnings growth forecast for next year Apellis Pharmaceuticals, Inc. (APLS)|Earnings growth forecast for next year BLTE (Belite Bio)|OCUL - Expected earnings per share growth for next year|HROW - Net earnings per share growth forecast for next year|Expected earnings per share trend next year VRDN (Viridian Therapeutics)|LENZ (LENZ Therapeutics, Inc.) - Expected earnings per share growth for next year|Oculis Holding AG - Expected earnings per share trend next year|Net earnings per share growth forecast for next year eyepointpharma.com|Earnings growth forecast for next year Kodiak Sciences Inc.|Net earnings per share growth forecast for next year Aldeyra Therapeutics Inc. (ALDX)|Net earnings per share growth forecast for next year KALA (KALA BIO)|Net earnings per share growth forecast for next year opusgtx.com IRD|Expected earnings per share trend next year OKYO|OTLK: Expected earnings per share growth for next year|CLSD (Clearside) - Projected earnings per share growth rate for next year|NBY: Earnings growth forecast for next year|Kiora Pharma (KPRX) - Earnings growth forecast for next year|ALIM (alimerasciences.com) - Earnings growth forecast for next year|eyenovia.com (EYEN) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year GHSI|OCUP (Ocuphire) - Expected earnings per share trend next year|Earnings growth forecast for next year OPT (Opthea Ltd)